

## Chronology

Year	Net Sales in US\$	Employees worldwide	Highlights
2016	1,338 Mil	4,700	<p>QIAGEN launches liquid biopsy workflow for GeneReader NGS System.</p> <p>QIAGEN launches “Digital NGS” solutions with unique Molecular Index Technology to reliably detect all genetic variation.</p> <p>QIAGEN launches QIAscout for single-cell isolation.</p>
2015	1,281 Mil	4,600	<p>QIAGEN introduces GeneReader NGS System the first end-to-end NGS workflow solution for actionable results from Sample to Insight.</p> <p>QIAGEN launches the world’s first regulatory approved companion diagnostic for lung cancer patients based on liquid biopsies.</p> <p>QIAGEN launches QuantiFERON®-TB Gold Plus – a new generation of the most accurate test for detecting latent tuberculosis infections.</p>
2014	1,346 Mil	4,300	<p>QIAGEN’s Sample to Insight solutions play an important role in the fight against the Ebola outbreak in Africa.</p> <p>QIAGEN signs the ninth framework agreement with a pharmaceutical company for the joint development of companion diagnostics.</p>
2013	1,306 Mil	4,015	<p>QIAGEN acquires Ingenuity Systems and CLC bio, creating leadership in solutions for analysis and interpretation of biological data.</p> <p>The FDA approves QIAGEN’s <i>therascreen</i> EGFR test as a companion diagnostic for <i>Gilotrif</i> in patients with non-small cell lung cancer.</p> <p>QIAGEN unveils its complete Sample to Insight solution for next-generation sequencing applications in clinical research &amp; diagnostics.</p>
2012	1,255 Mil	4,000	<p>QIAGEN gains FDA approval for its KRAS test as companion diagnostic for <i>Erbix</i> in metastatic colorectal cancer patients.</p> <p>Start of a comprehensive initiative to develop complete next-generation sequencing workflow solutions for clinical applications.</p> <p>QIAGEN restructures the company with the creation of two Business Areas – “Life Sciences” and “Molecular Diagnostics.”</p>
2011	1,170 Mil	3,900	<p>Acquisition of QuantiFERON technology that allows for the detection of many diseases far earlier than other methods.</p> <p>QIAGEN acquires a majority stake in the French company Ipsogen and gains access to a leading portfolio of blood cancer tests.</p> <p>Further expansion in Asia with new subsidiaries in India and Taiwan.</p>
2010	1,087 Mil	3,600	<p>QIAGEN launches QIAsymphony RGQ, a highly flexible modular automation platform streamlining entire laboratory workflows.</p> <p>Acquisition of point-of-need ESEQuant detection technology, with portable, affordable devices that generate results in 5 to 15 minutes.</p>

<b>2009</b>	1,010 Mil	3,400	<p>QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases.</p> <p>QIAGEN acquires DxS Ltd., securing a leadership position in personalized healthcare.</p> <p>QIAGEN technologies play a key role in the fight against the global Swine Flu pandemic.</p> <p>With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result.</p>
<b>2008</b>	893 Mil	3,000	<p>Acquisition of Pyrosequencing, a detection technology that works on a single base-pair level and allows the identification of unknown DNA sequences or mutations.</p> <p>QIASymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows.</p>
<b>2007</b>	649.8 Mil	2,600	<p>QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics.</p> <p>QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products.</p>
<b>2006</b>	465.8 Mil	1,800	<p>QIAGEN acquires an assay technology which allows for the testing of multiple pathogens in a single run (“multiplexing”).</p> <p>QIAGEN establishes its Asia regional headquarters in Shanghai.</p>
<b>2005</b>	398 Mil	1,600	<p>QIAGEN acquires a leading position in molecular diagnostics by adding various PCR-based molecular tests to its portfolio.</p> <p>Development of the <i>artus</i> influenza kit for the rapid detection of all known variants of the Avian Flu virus H5N1.</p> <p>Launch of the first human whole genome siRNA set worldwide. siRNAs are molecules that can shut down the activity of individual genes.</p>
<b>2004</b>	380 Mil	1,300	<p>QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE-mark.</p>
<b>2002</b>	298 Mil	1,600	<p>Relocation of US headquarters from Valencia, CA, to Germantown, MD.</p>
<b>2001</b>	263 Mil	1,550	<p>QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification.</p>
<b>1999</b>	158 Mil	900	<p>PreAnalytiX, a joint venture with BD and Company, is established.</p>
<b>1998</b>	120 Mil	800	<p>QIAGEN significantly expands its capabilities in automation.</p>
<b>1997</b>	75 Mil	600	<p>Initial Public Offering is completed on Deutsche Börse, Frankfurt.</p>
<b>1996</b>	54 Mil	450	<p>QIAGEN N.V. (Holding) established in Venlo, The Netherlands.</p> <p>Initial Public Offering is completed on NASDAQ, New York.</p> <p>QIAGEN introduces the BioRobot 9600, its first bench-top workstation, which automates purification technologies.</p>
<b>1986</b>	100,000	5	<p>QIAGEN revolutionizes molecular biology by introducing the first “Plasmid-Kit.” It reduces the time needed for the preparation of plasmids, ring-shaped DNA molecules from bacteria, from 2-3 days to 2 hours.</p>

1984

0

2

QIAGEN is founded in Düsseldorf, Germany.

---